Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paratek's Omadacycline May Face Mortality Questions With Proposed Pneumonia Indication

Executive Summary

US FDA advisory committee will consider "noteworthy" imbalance in deaths in Paratek's trial in community-acquired bacterial pneumonia; agency could not determine cause, briefing documents note.

You may also be interested in...



Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch

Company still mulling pricing for broad-spectrum antibiotic Nuzyra (omadacycline), which is set to launch in the US in the first quarter, following FDA approval Oct. 2.

Paratek's Omadacycline Development May Hinge On Moxifloxacin Mortality

If moxifloxacin, the comparator in omadacycline's CABP trial, is thought to have an unusually low mortality rate, then the mortality imbalance seen between arms in the study may not seem so worrying. 

Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern

Most FDA advisory committee members say potential mortality issue seen in community acquired bacterial pneumonia patients can be addressed postmarket.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel